尿CXCL10水平对PICU重症患儿死亡风险的预测价值

doi:10.12372/jcp.2024.23e0856

Abstract

Abstract:

Objective To investigate the predictive value of urinary CXC motif chemokine ligand 10 (uCXCL10) in the risk of death in critically ill children during their stay in the pediatric intensive care unit (PICU). Methods A total of 323 critically ill children admitted to PICU from September to December 2016 and from December 2017 to January 2018 were selected as the research objects. The patients were divided into survival group (295 cases) and death group (28 cases) according to the outcome during hospitalization in PICU, and the clinical characteristics of the children were compared between the groups. The uCXCL10 levels were serially measured during the first week after PICU admission using an enzyme-linked immunosorbent assay. Stepwise multivariate linear regression analysis were used to determine the correlation between uCXCL10 levels and clinical variables. Multivariate logistic regression analysis were performed to investigate the association of uCXCL10 with mortality after adjusting for confounders. The area under the ROC curve (AUC) was calculated to assess the predictive value of uCXCL10 in mortality of critically ill children. Results The initial and maximum values of uCXCL10 in the death group were significantly higher than those in the survival group (P<0.05). Both stepwise multivariate linear regression and multivariate logistic regression analysis showed that the initial and maximum values of uCXCL10 were significantly associated with mortality (P<0.05). The AUC values of initial and maximum uCXCL10 for predicting death in critically ill children were 0.780 (95%CI: 0.689-0.872, P<0.001) and 0.846 (95%CI: 0.769-0.923, P<0.001), respectively. Conclusion The uCXCL10 is an independent predictor of death in critically ill children.

Key words: mortality risk, urinary CXC motif chemokine ligand 10, predictive value, child

FENG Lian, HU Junlong, HUANG Hui, LI Xiaozhong, LI Yanhong. Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU[J].Journal of Clinical Pediatrics, 2024, 42(7): 631-636.

Figures/Tables 4

References 30

[1]	Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM[J]. Intensive Care Med, 2002, 28(2): 204-207.
[2]	Joyce EL, Crana CM, Yabes J, et al. Validation of an electronic pediatric index of mortality 2 score in a mixed quaternary PICU[J]. Pediatr Crit Care Med, 2020, 21(8): e572-e575.
[3]	Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the sepsis-3 definitions in critically ill children[J]. JAMA Pediatr, 2017, 171(10): e172352.
[4]	Tonial CT, Costa C, Andrades G, et al. Performance of prognostic markers in pediatric sepsis[J]. J Pediatr (Rio J), 2021, 97(3): 287-294.
[5]	Rey C, Fortenberry JD. Prognostic markers for pediatric septic shock: which ones, when, and how?[J]. Intensive Care Med, 2013, 39(10): 1851-1853. doi: 10.1007/s00134-013-3027-4 pmid: 23900580
[6]	Anil AB, Anil M, Yildiz M, et al. The importance of microalbuminuria in predicting patient outcome in a PICU[J]. Pediatr Crit Care Med, 2014, 15(5): e220-e225.
[7]	Nismath S, Rao SS, Baliga BS, et al. Comparative validity of microalbuminuria versus clinical mortality scores to predict pediatric intensive care unit outcomes[J]. Clin Exp Pediatr, 2020, 63(1): 20-24. doi: 10.3345/kjp.2018.07220 pmid: 31401824
[8]	Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases[J]. Autoimmun Rev, 2014, 13(3): 272-280. doi: 10.1016/j.autrev.2013.10.010 pmid: 24189283
[9]	Elemam NM, Talaat IM, Maghazachi AA. CXCL10 chemokine: a critical player in RNA and DNA viral infections[J]. Viruses, 2022, 14(11): 2445.
[10]	Gao J, Wu L, Wang S, et al. Role of chemokine (C-X-C Motif) ligand 10 (CXCL10) in renal diseases[J]. Mediators Inflamm, 2020: 6194864.
[11]	Liu M, Guo S, Hibbert JM, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications[J]. Cytokine Growth Factor Rev, 2011, 22(3): 121-130.
[12]	Jekarl DW, Kim JY, Ha JH, et al. Diagnosis and prognosis of sepsis based on use of cytokines, chemokines, and growth factors[J]. Dis Markers, 2019: 1089107.
[13]	Erez DL, Denburg MR, Afolayan S, et al. Acute kidney injury in children after hematopoietic cell transplantation is associated with elevated urine CXCL10 and CXCL9[J]. Biol Blood Marrow Transplant, 2020, 26(7): 1266-1272.
[14]	Huang H, Zhou H, Wang W, et al. Prediction of acute kidney injury, sepsis and mortality in children with urinary CXCL10[J]. Pediatr Res, 2022, 92(2): 541-548.
[15]	Hoste E, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury[J]. Nat Rev Nephrol, 2018, 14(10): 607-625. doi: 10.1038/s41581-018-0052-0 pmid: 30135570
[16]	Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: S0140-6736(19)32989-7 pmid: 31954465
[17]	Amecican Academy of Pediatrics, Commitee on Hospitial Care and Society of Critial Care, Society of Critial Care Medicine, et al. Guidelines for developing admission and discharge policies for the pediatric[J]. Pediatrics, 1999(103): 840-842.
[18]	Weiss SL, Peters MJ, Alhazzani W, et al. Executive summary: surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children[J]. Pediatr Crit Care Med, 2020, 21(2): 186-195.
[19]	Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184.
[20]	Fang F, Hu X, Dai X, et al. Subclinical acute kidney injury is associated with adverse outcomes in critically ill neonates and children[J]. Crit Care, 2018, 22(1): 256.
[21]	Herzig DS, Luan L, Bohannon JK, et al. The role of CXCL10 in the pathogenesis of experimental septic shock[J]. Crit Care, 2014, 18(3): R113.
[22]	Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases[J]. Autoimmun Rev, 2009, 8(5): 379-383. doi: 10.1016/j.autrev.2008.12.002 pmid: 19105984
[23]	Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers[J]. Expert Rev Mol Diagn, 2011, 11(5):487-496. doi: 10.1586/ERM.11.26 pmid: 21707457
[24]	Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans[J]. Clin Transl Sci, 2008, 1(3): 200-208. doi: 10.1111/j.1752-8062.2008.00053.x pmid: 19212447
[25]	程创, 石中全. miR-16-5p靶向抑制CXCL10表达减轻脂多糖诱导的HK-2人肾小管上皮细胞损伤[J]. 细胞与分子免疫学杂志, 2022, 38(3): 218-223.
[26]	Kirita Y, Wu H, Uchimura K, et al. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury[J]. Proc Natl Acad Sci U S A, 2020, 117(27): 15874-15883.
[27]	Lehmann JM, Claus K, Jansen C, et al. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality[J]. Liver Int, 2018, 38(5): 875-884. doi: 10.1111/liv.13610 pmid: 29105936
[28]	Landreneau MJ, Mullen MT, Messe SR, et al. CCL2 and CXCL10 are associated with poor outcome after intracerebral hemorrhage[J]. Ann Clin Transl Neurol, 2018, 5(8): 962-970.
[29]	Tinel C, Vermorel A, Picciotto D, et al. Deciphering the prognostic and predictive value of urinary CXCL10 in kidney recipients with BK virus reactivation[J]. Front Immunol, 2020, 11: 604353.
[30]	Tinel C, Devresse A, Vermorel A, et al. Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection[J]. Am J Transplant, 2020, 20(12): 3462-3476.

项目	存活组（n=295）	死亡组（n=28）	统计量	P
年龄[M(P₂₅~P₇₅)]/月	17.0(3.1~56.0)	20.5(8.4~71.8)	Z=1.23	0.194
体重[M(P₂₅~P₇₅)]/kg	11.0(6.6~18.0)	12.5(7.9~23.8)	Z=1.03	0.303
性别(男)[n(%)]	197(66.8)	21(75.0)	χ²=0.78	0.375
PRISM Ⅲ[M(P₂₅~P₇₅)]/分	3(0~8)	14(7~28.8)	Z=5.69	<0.001
AKI[n(%)]	34(11.5)	15(53.6)	χ²=31.94	<0.001
AKI 1期[n(%)]	15(5.1)	6(21.5)	χ²=11.88	0.003
AKI 2期[n(%)]	13(4.4)	0(0.0)
AKI 3期[n(%)]	6(2.0)	9(32.1)
脓毒症[n(%)]	107(36.3)	14(50.0)	χ²=2.06	0.151
MODS[n(%)]	16(5.4)	18(64.3)	χ²=87.93	<0.001
休克/DIC[n(%)]	21(7.1)	9(32.1)	χ²=16.15	<0.001
MV[n(%)]	58(19.7)	25(89.3)	χ²=64.92	<0.001
RRT[n(%)]	12(4.1)	4(14.3)	χ²=3.71	0.054
正性肌力药[n(%)]	22(7.5)	9(32.1)	χ²=15.23	<0.001
利尿剂[n(%)]	25(8.5)	12(42.9)	χ²=26.51	<0.001
激素[n(%)]	161(54.6)	21(75.0)	χ²=4.34	0.037
抗生素[n(%)]	231(78.3)	24(85.7)	χ²=0.85	0.358
PICU时长[M(P₂₅~P₇₅)]/ h	87.5(46.0~148.0)	167.8(63.0~420.0)	Z=2.76	0.006
uCXCL10初始值/uCr[M(P₂₅~P₇₅)]/ng·mg^-1	0.09(0.04~0.25)	0.80(0.14~2.98)	Z=4.90	<0.001
uCXCL10最大值/uCr[M(P₂₅~P₇₅)]/ng·mg^-1	0.11(0.05~0.35)	2.04(0.45~3.75)	Z=6.50	<0.001

因素	uCXCL10初始值			uCXCL10最大值
因素	β	S.E.	P	β	S.E.	P
体重	NA	NA	NA	-0.009	0.003	0.005
AKI分期	NA	NA	NA	0.124	0.051	0.015
脓毒症	0.189	0.076	0.013	0.192	0.072	0.008
休克/DIC	0.384	0.130	0.003	0.406	0.127	0.001
临床结局	0.682	0.132	<0.001	0.733	0.132	<0.001

因素	OR	95%CI	P	AOR	95%CI	P
尿CXCL10初始值	4.295	2.458~7.503	<0.001	4.079^1）	1.676~9.929	0.002
尿CXCL10最大值	6.118	3.343~11.453	<0.001	5.421^1）	2.114~13.904	<0.001

Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 30

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LI Benshang, YANG Liu. Challenges and prospects of CAR-T treatment for pediatric disease [J]. Journal of Clinical Pediatrics, 2024, 42(7): 573-577.
[2]	LU Jun. The clinical significance and management strategies of B cell aplasia following CD19 CAR-T cell therapy in pediatric patients [J]. Journal of Clinical Pediatrics, 2024, 42(7): 578-582.
[3]	SHANG Qianwen, ZHANG Yongzhan, LU Aidong, JIA Yueping, ZUO Yingxi, DING Mingming, ZHANG Leping, ZENG Huimin. The efficacy and safety of modified CLAG regimen for relapsed or refractory acute myeloid leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 589-594.
[4]	ZHAO Fenghua, ZHANG Yue, SUN Jin, YAN Shuangqin, LYU Lanqiu, MU Lijuan, YANG Jing, LUO Yan, YAN Dongmei, ZHAO Dongmei. Child-rearing problems of premature/low birth weight children aged 0 to 3 years: a multicenter cross-sectional study [J]. Journal of Clinical Pediatrics, 2024, 42(7): 606-612.
[5]	CHEN Zongzong, LI Xiaojing, HOU Chi, PENG Bingwei, WU Wenxiao, ZHU Haixia, WU Wenlin, TIAN Yang, CHEN Wenxiong. Clinical features and prognosis of immune-related brainstem encephalitis in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 626-630.
[6]	CHEN Ye, ZHU Shanliang, YANG Shiwei, CHEN Jun, HUA Lichun, TANG Ying. The value of two-dimensional speckle tracking imaging in the assessment of left ventricular function in children with influenza A-related myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(7): 648-653.
[7]	WANG Huiying, TANG Jiazhong, SHANG Wenyuan, HUANG Jihong, LU Yanan, CHEN Sun. Analysis of factors influencing mechanical ventilation duration after surgery for congenital heart disease [J]. Journal of Clinical Pediatrics, 2024, 42(7): 654-658.
[8]	LI Niu, WANG Jian. Current status of database construction for rare diseases in children [J]. Journal of Clinical Pediatrics, 2024, 42(7): 663-666.
[9]	MA Tao, LU Jie, XU Hui, ZHAO Shunying, LI Huimin. Clinical characteristics of extrapulmonary tuberculosis in 473 children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 491-496.
[10]	GONG Ling, SHU Chang, RAN Haibo. Clinical characteristics and treatment outcomes of connective tissue disease-associated interstitial lung disease in children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 503-508.
[11]	LIANG Jiawei, MA Xiaohui, JIA Xuan. Study on the application value of the new Lake Louise criteria in children with myocarditis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 526-532.
[12]	FAN Na, WANG Chunhui, ZHANG Anding, ZENG Lingchao, LI Yuanxia, LIN Yan, SHANG Lei, ZHANG Xinhui, HE Xiaobao, QI Ke, JIANG Xun. Correlation between functional constipation and the formation of appendiceal fecaliths in children with acute appendicitis [J]. Journal of Clinical Pediatrics, 2024, 42(6): 533-537.
[13]	MAO Meng, SHAO Jie, CHEN Jinjin, SHEN Lixiao. Interpretation of Catch-up growth in infants and young children with faltering growth: expert opinion to guide general clinicians [J]. Journal of Clinical Pediatrics, 2024, 42(5): 390-398.
[14]	XU Jiangshan, XU Xin, HE Shuang, LIU Qian, TIAN Jie, LYU Tiewei. Single center clinical analysis of radiofrequency ablation for children with cardiac enlargement and ventricular preexcitation [J]. Journal of Clinical Pediatrics, 2024, 42(5): 407-413.
[15]	LI Zhijuan, BAO Ying, HUANG Huimei, ZHANG Min, WANG Ying, NIU Yunhe, YANG Nan, SUO Lei, LIANG Nan. Clinical features and factors associated with diabetes mellitus in children-onset systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2024, 42(5): 419-424.